Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19?

Benedetta Terziroli Beretta-Piccoli^{1

2

3}, Ana Lleo^{4

5}

Affiliations

¹ Epatocentro Ticino, Lugano, Switzerland.
² King's College London Faculty of Life Sciences & Medicine, Institute of Liver Studies, MowatLabs, London, UK.
³ Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
⁴ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
⁵ Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Editorial

Benedetta Terziroli Beretta-Piccoli et al. Liver Int. 2022 Feb.

. 2022 Feb;42(2):274-276.

doi: 10.1111/liv.15138.

Benedetta Terziroli Beretta-Piccoli^{1

2

3}, Ana Lleo^{4

5}

¹ Epatocentro Ticino, Lugano, Switzerland.
² King's College London Faculty of Life Sciences & Medicine, Institute of Liver Studies, MowatLabs, London, UK.
³ Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
⁴ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
⁵ Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

No abstract available

Comment on

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.
Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Efe C, et al. Liver Int. 2022 Mar;42(3):607-614. doi: 10.1111/liv.15121. Epub 2021 Dec 13. Liver Int. 2022. PMID: 34846800

1. Zahid MN, Perna S. Continent-wide analysis of COVID 19: total cases, deaths, tests, socio-economic, and morbidity factors associated to the mortality rate, and forecasting analysis in 2020-2021. Int J Environ Res Public Health. 2021;18:5350.
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
1. Kim D, Adeniji N, Latt N, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. Clin Gastroenterol Hepatol. 2021;19:1469-1479.e19.
1. Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063-1071.
1. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725-732.